NEW YORK, April 6 Reportlinker.com announces that a new market research report is available in its catalogue:
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
Advertisement
http://www.reportlinker.com/p0185998/Epigenomics-Emerging-Opportunities-in-Biomarkers-Diagnostics-and-Therapeutics.html
THIS REPORT:
Provides a comprehensive overview of the global market for epigenomics
Advertisement
Describes the major epigenomics technologies impacting the market today and emerging opportunities in biomarkers, diagnostics and therapeutics
Contains global market forecasts for epigenomics, with trends and forecasts for growth through 2014
Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs and cloning/tissue engineering
Discusses industry structure including, mergers and acquisitions, distribution of products, government regulation and industry trends
Profiles the most competitive businesses in the industry.
Chapter- 1: INTRODUCTION
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 2
SCOPE OF REPORT 2
METHODOLOGY 2
INFORMATION SOURCES 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4
CHAPTER TWO: SUMMARY
SUMMARY 5
SUMMARY TABLE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, 2008-2014 ($ MILLIONS) 6
SUMMARY (CONTINUED) 7
CHAPTER THREE: OVERVIEW
INTRODUCTION 8
THE NEW PARADIGM OF EPIGENOMICS 8
FIGURE 1 EPIGENOMICS: A NEW PARADIGM 9
HOW EPIGENOMICS FITS WITHIN GENOMICS 10
TABLE 1 GENOMICS PLATFORMS 10
HOW EPIGENOMICS FITS WITHIN ... (CONTINUED) 11
TECHNICAL SCOPE OF THIS REPORT 12
TABLE 2 TECHNOLOGY SCOPE OF THIS REPORT 12
MARKET POTENTIAL OF EPIGENOMICS 13
TABLE 3 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 13
EPIGENOMICS PRODUCTS 14
RESEARCH TOOLS AND REAGENTS 14
DIAGNOSTICS 15
DRUGS 15
FIGURE 2 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND INDICATION, JANUARY 2010 16
GROWTH DRIVING FORCES 17
GROWTH IN LIFE SCIENCE FUNDING 17
CREATION OF EPIGENOMIC MAPS 17
AGING POPULATION IN DEVELOPED COUNTRIES 17
NEED FOR BETTER CANCER THERAPIES 17
GROWTH IN PERSONALIZED MEDICINE 18
WHY EPIGENETIC TECHNOLOGY IS IMPORTANT 18
FIGURE 3 EPIGENETIC PROCESSES CAN GENERATE ABNORMAL CELLS DURING CELL DEVELOPMENT 18
LIFE CYCLE STATUS OF EPIGENOMICS TECHNOLOGIES 19
HISTORICAL BACKGROUND 20
TABLE 4 HISTORICAL OVERVIEW OF EPIGENOMICS 20
HISTORICAL BACKGROUND (CONTINUED) 21
THE EPIGENOMICS INDUSTRY 22
TABLE 5 EPIGENOMICS INDUSTRY KEY COMPANIES 23
THE EPIGENOMICS INDUSTRY (CONTINUED) 24
CHAPTER FOUR: EPIGENETIC TECHNOLOGIES
INTRODUCTION 25
EPIGENETIC ANALYSIS TECHNOLOGIES 25
TABLE 6 EPIGENETIC ANALYSIS TECHNOLOGIES 26
STATUS OF DNA AND HISTONE ANALYSIS TECHNOLOGIES 26
TABLE 7 STATUS OF DNA METHYLATION AND HISTONE ANALYSIS TECHNOLOGIES 26
TABLE 7 (CONTINUED) 27
DNA AND HISTONE ANALYSIS WORKFLOW 28
FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS WORKFLOW 29
DNA METHYLATION 29
METHYLATED CYTOSINE--A FIFTH BASE 29
FIGURE 5 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION 30
BIOLOGICAL ROLE OF DNA METHYLATION 30
TABLE 8 BIOLOGICAL ROLES OF DNA METHYLATION 31
DNA METHYLTRANSFERASE ENZYMES 32
CPG ISLANDS 33
TABLE 9 DESCRIPTION OF CPG ISLANDS 34
HISTONE METHYLATION AND ACETYLATION 35
HISTONES 35
HISTONE MODIFICATIONS 36
FIGURE 6 ACETYLATION OF HISTONE TAIL REGIONS 36
HISTONE ACETYLATION AND METHYLATION ENZYMES 37
FIGURE 7 HISTONE ACETYLATION AND METHYLATION ENZYMES 38
Histone Acetyl Transferases (HAT) 38
Histone Deacetylases (HDAC) 39
TABLE 10 HDAC ENZYMES CLASSES 39
Histone Methyltransferases and Demethylases 39
INAPPROPRIATE METHYLATION AND ACETYLATION 40
TABLE 11 MECHANISMS FOR INAPPROPRIATE METHYLATION AND ACETYLATION 40
CHAPTER FIVE: EPIGENOMIC ANALYSIS TECHNOLOGIES
IMPORTANCE OF EPIGENOMIC RESEARCH TOOLS 41
DNA METHYLATION RESEARCH TOOLS 42
TABLE 12 DNA METHYLATION ANALYSIS ASSAYS 42
DNA METHYLATION RESEARCH TOOLS (CONTINUED) 43
TABLE 13 EMERGING DNA METHYLATION TECHNOLOGIES 44
TABLE 14 ACRONYMS FOR DNA METHYLATION TECHNOLOGIES 45
DNA METHYLATION ANALYSIS WORKFLOW 46
FIGURE 8 METHYLATED DNA ANALYSIS WORKFLOW 47
DNA METHYLATION ANALYSIS METHODS BY COVERAGE AND THROUGHPUT 47
TABLE 15 DNA METHYLATION TECHNOLOGIES BY COVERAGE AND THROUGHPUT 48
DNA METHYLATION ANALYSIS TYPES BY WORKFLOW 49
TABLE 16 EXAMPLES OF DNA METHYLATION ASSAYS 49
DNA METHYLATION ANALYSIS: UPSTREAM TECHNOLOGIES 50
TABLE 17 METHYLATION RECOGNITION TECHNOLOGIES 50
RESTRICTION ENZYME-BASED METHODS 51
FIGURE 9 ANALYSIS OF DNA METHYLATION BY RESTRICTION ENZYMES 52
BISULFITE-BASED METHODS 52
Bisulfite-based Methods (Continued) 53
FIGURE 10 BISULFITE CONVERSION OF DNA 54
Analysis of Low Complexity DNA 55
AFFINITY-BASED METHODS 56
CHALLENGE OF HIGH BACKGROUND METHYLATED DNA 57
GENOME WIDE DNA METHYLATION ANALYSIS 57
TABLE 18 DNA METHYLATION ANALYSIS TECHNIQUES BY GENOME RESOLUTION 58
HISTONE EPIGENETIC ANALYSIS TECHNOLOGIES 59
TABLE 19 CHIP ASSAYS 60
CHIP-CHIP AND CHIP-SEQ 61
FIGURE 11 WORKFLOW SCHEMATIC FOR CHIP PLATFORMS 61
TABLE 20 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES 62
EMERGING DOWNSTREAM EPIGENETIC ANALYSIS PLATFORMS 63
MICROARRAYS 63
TABLE 21 MICROARRAY TYPES 63
TABLE 22 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 64
DNA Microarray Technologies 65
FIGURE 12 MICROARRAY FEATURE DENSITY 66
FIGURE 13 MICROARRAY RESOLUTION 66
TABLE 23 MICROARRAY GENOME CONTENT 67
TABLE 24 DNA MICROARRAY PLATFORM FEATURES 68
TABLE 25 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 69
DNA Microarray ... (Continued) 70
Microarrays for Epigenetics Analysis 71
FIGURE 14 MICROARRAYS ENHANCE MULTIPLEX CAPABILITIES OF EPIGENETICS ASSAYS 71
Microarrays for ... (Continued) 72
NEXT GENERATION DNA SEQUENCING 73
FIGURE 15 DNA SEQUENCING PLATFORMS 73
Next Generation DNA ... (Continued) 74
Next Generation DNA ... (Continued) 75
FIGURE 16 NEXT GENERATION SEQUENCING TECHNOLOGIES WORKFLOW OVERVIEW 76
SERIAL ANALYSIS OF GENE EXPRESSION 77
ANTIBODIES 78
ALTERNATIVES TO ANTIBODIES IN UPSTREAM ANALYSIS STEP 79
ALTERNATIVES TO ANTIBODIES IN ... (CONTINUED) 80
CHAPTER SIX: EPIGENETICS DIAGNOSTICS TECHNOLOGIES
WHAT IS A BIOMARKER?
TABLE 26 ROLE OF BIOMARKERS IN CLINICAL TRIAL DESIGN
DNA METHYLATION AS A CANCER BIOMARKER
DNA METHYLATION IN CANCER ETIOLOGY
TABLE 27 BIOLOGICAL RATIONALE FOR DNA METHYLATION CANCER BIOMARKERS
TABLE 28 CANCER-RELATED CELL PATHWAYS AND GENES AFFECTED BY HYPER-METHYLATION
Cell Cycle Control
Cell Invasion and Adhesion
DNA Damage Repair
Growth Factor Response
Regulation of Apoptosis
Hormonal Response
Cytokine Signaling
TABLE 29 CANCER-RELATED EPIGENETIC CHANGES
COMPARISON OF MOLECULAR BIOMARKER PLATFORMS
TABLE 30 COMPARISON OF KEY CANCER BIOMARKER TECHNOLOGY PLATFORMS
Comparison of Molecular ... (Continued)
Comparison of Molecular ... (Continued)
ASSESSMENT OF DNA METHYLATION BIOMARKER COMPETITIVE POSITION
EPIGENETIC BIOMARKER GENES
TABLE 31 PUBLISHED DNA METHYLATION BIOMARKER GENES FOR CANCERS
TABLE 32 DIFFERENTIALLY METHYLATED GENES IN NEUROLOGIC AND CARDIOVASCULAR DISORDERS
BIOMARKER DISCOVERY PROCESS
METHYLATION BIOMARKER DISCOVERY TECHNOLOGIES
TABLE 33 DNA METHYLATION ANALYSIS TECHNOLOGIES IN BIOMARKER DISCOVERY
GENOME-WIDE SCANNING FOR BIOMARKER DISCOVERY
CASE STUDY: FROM RESEARCH TOOLS TO BIOMARKERS
IN-VITRO DIAGNOSTIC DEVELOPMENT PROCESS
PHASE 1: BIOMARKER DISCOVERY
PHASE 2: BIOMARKER VALIDATION
PHASE 3: FORMAL KIT DEVELOPMENT
PHASE 4: CLINICAL VALIDATION
PHASE 5: REGULATORY REVIEW AND APPROVAL
FUTURE STATUS OF DNA METHYLATION BIOMARKERS
TABLE 34 TECHNICAL HURDLES FOR DEVELOPMENT OF METHYLATION EPIGENETIC CANCER BIOMARKERS
FUTURE STATUS OF DNA ... (CONTINUED)
CHAPTER SEVEN: EPIGENETIC CANCER DRUG TECHNOLOGIES
INTRODUCTION 102
EPIGENETICS IN TUMORIGENESIS 102
EPIGENETIC GENES IN HUMAN CANCER 102
TABLE 35 EPIGENETIC GENES ALTERED IN HUMAN CANCERS 103
TABLE 35 (CONTINUED) 104
EPIGENETIC ENZYME DRUG TARGETS 105
FIGURE 17 HISTONE DEACETYLASE REACTION 105
TABLE 36 STATUS OF INHIBITORS OF EPIGENETIC ENZYMES TARGETING HISTONES 106
HISTONE DEACETYLASE INHIBITORS 107
BENEFITS OF HDAC INHIBITORS 108
HDAC INHIBITOR DRUG CLASSES 109
TABLE 37 HDAC INHIBITOR CLASSES AND RELATIVE POTENCY 109
Hydroxamates 110
FIGURE 18 CHEMICAL STRUCTURE OF TRICHOSTATIN A, A HYDROXAMATE CLASS HDAC INHIBITOR 110
Aliphatic Acids 110
FIGURE 19 PHENYLBUTYRIC ACID, AN ALIPHATIC ACID CLASS HDAC INHIBITOR 111
Cyclic Tetrapeptides 111
FIGURE 20 APICIDIN A, A CYCLIC TETRAPEPTIDE CLASS HDAC INHIBITOR 111
Benzamides 112
FIGURE 21 ENTINOSTAT, A BENZAMIDE CLASS HDAC INHIBITOR 112
HDAC INHIBITOR TECHNOLOGY TRENDS 113
TABLE 38 HDAC INHIBITOR DRUG TECHNOLOGY TRENDS 113
Enzyme Selectivity 113
Enzyme Selectivity (Continued) 114
TABLE 39 HDAC INHIBITOR CLASS I AND II SELECTIVITY 115
Potency 115
Improvements in Drug-like Properties 116
SELECTIVE HDAC COMPOUNDS CAN PROVIDE COMPETITIVE ADVANTAGE 116
FIGURE 22 DISEASE HDAC ISOFORM GENE EXPRESSION PROFILE 117
CHEMICAL DESIGN IS THE KEY TO HDAC INHIBITOR SELECTIVITY 118
FIGURE 23 COMMON STRUCTURAL COMPONENT MOTIFS OF VORINOSTAT 118
Chemical Design ... (Continued) 119
HDAC INHIBITORS IN COMBINATION THERAPIES 120
TABLE 40 DRUG CLASSES THAT CAN BE USED IN COMBINATION WITH HDAC INHIBITORS 121
HDAC INHIBITORS AS THERAPIES OUTSIDE CANCER 122
DERMATOLOGICAL DISORDERS 123
PARASITIC DISEASES 123
NEURODEGENERATIVE DISEASES 124
DIABETES 125
INFLAMMATORY DISEASES 125
IMMUNE DISORDERS 125
DNA METHYLTRANSFERASE INHIBITORS 126
FIGURE 24 LEAD DNMT INHIBITOR COMPOUNDS 126
TECHNICAL CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 127
TABLE 41 FUTURE CHALLENGES FOR EPIGENETIC DRUG DEVELOPMENT 127
TECHNICAL CHALLENGES FOR ... (CONTINUED) 128
CHAPTER EIGHT: EPIGENETICS CLONING AND CELLULAR
SOMATIC CELL NUCLEAR TRANSFER 129
FIGURE 25 SOMATIC CELL NUCLEAR TRANSFER 129
TABLE 42 TECHNOLOGY OPPORTUNITIES IN SOMATIC CELL NUCLEAR TRANSFER 130
APPLICATIONS 130
REPROGRAMMING FACTORS 131
FIGURE 26 EPIGENETIC PROGRAMMING OF STEM CELLS 132
QUALITY CONTROL ASSAYS IN CELLULAR THERAPIES 132
Tissue Engineering 133
Stem Cell Therapies 133
Non-stem Cell Therapies 134
CHAPTER NINE: LARGE SCALE REGIONAL EPIGENOMICS PROJECTS
LARGE SCALE REGIONAL EPIGENOMICS PROJECTS 135
TABLE 43 REGIONAL EPIGENOMICS INITIATIVES 136
TABLE 43 (CONTINUED) 137
EUROPE 137
UNITED STATES 138
ASIA 139
Asia (Continued) 140
CHAPTER TEN: CANCER DIAGNOSTICS APPLICATIONS
ATTRACTIVE CANCER INDICATIONS FOR SCREENING MARKETS 141
FIGURE 27 CANCER SCREENING OPPORTUNITY MATRIX FOR MOLECULAR DIAGNOSTICS 142
EPIGENETICS AS A SCREENING PLATFORM 143
FIGURE 28 NEW EPIGENETIC SCREENING PARADIGM 144
DIAGNOSTIC SENSITIVITY AND SPECIFICITY 144
FIGURE 29 SENSITIVITY AND SPECIFICITY 145
STATUS OF DIAGNOSTICS TESTS FOR SELECTED CANCER INDICATIONS 146
BLADDER CANCER 146
CARCINOMA OF UNKNOWN PRIMARY (CUP) 147
TABLE 44 COMMERCIAL MOLECULAR DIAGNOSTIC PLATFORMS FOR TISSUE OF ORIGIN TESTS 148
CERVICAL CANCER 149
TABLE 45 COMMERCIAL LANDSCAPE FOR HPV TESTS 150
Cervical Cancer (Continued) 151
COLORECTAL CANCER 152
Colorectal Cancer Existing Screening Tests 152
TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER 153
TABLE 47 ACCURACY OF EXISTING COLORECTAL SCREENING TESTS 154
Molecular Colorectal Cancer Diagnostics Tests 155
TABLE 48 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS 155
Molecular ... (Continued) 156
TABLE 49 COMPETITIVE SITUATION FOR CONVENTIONAL AND MOLECULAR COLON CANCER SCREENING TESTS 157
Colorectal Cancer Diagnostics Tests 158
GASTRIC CANCER 158
LUNG CANCER 159
Lung Cancer (Continued) 160
OVARIAN CANCER 161
TABLE 50 OVARIAN CANCER SCREENING TESTS 161
TABLE 51 OVARIAN CANCER DIAGNOSTIC TEST STATUS 162
PANCREATIC CANCER 163
PEDIATRIC CANCERS 163
PROSTATE CANCER 164
Prostate Cancer (Continued) 165
PERSONALIZED TREATMENT EPIGENETIC-BASED TESTS 166
KEY CLINICAL REQUIREMENTS FOR AN EPIGENETIC-BASED DIAGNOSTICS TEST 166
TABLE 52 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY 167
DNA METHYLATION DIAGNOSTICS PIPELINE 168
TABLE 53 EPIGENETIC DIAGNOSTICS DEVELOPMENT PIPELINE 168
TABLE 53 (CONTINUED) 169
DNA METHYLATION DIAGNOSTICS ... (CONTINUED) 170
CHAPTER ELEVEN: THERAPEUTIC APPLICATIONS
EPIGENETIC DRUG CLINICAL TRIALS 171
TABLE 54 APPROVED EPIGENETIC DRUGS 171
TABLE 55 NEXT GENERATION EPIGENETIC DRUGS 171
FIGURE 30 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY DRUG CLASS AND CANCER TYPE, JANUARY 2010 172
FIGURE 30 (CONTINUED) 173
FIGURE 31 ACTIVE CANCER EPIGENETIC DRUG CLINICAL TRIALS, BY PHASE AND INDICATION, JANUARY 2010 174
FIGURE 32 CURRENT EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY DRUG AND TRIAL TYPE, JANUARY 2010 175
FIGURE 33 ACTIVE EPIGENETIC CANCER DRUG CLINICAL TRIALS, BY CLINICAL PHASE AND TRIAL TYPE, JANUARY 2010 176
EPIGENETIC DRUG NOMENCLATURE 177
TABLE 56 EPIGENETIC DRUG NOMENCLATURE TABLE 177
TABLE 56 (CONTINUED) 178
HDAC INHIBITOR CLINICAL TRIALS 178
TABLE 57 HDAC INHIBITOR CLINICAL TRIALS SUMMARY 178
TABLE 57 (CONTINUED) 179
HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 179
HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 180
TABLE 58 MBCD0103 INHIBITS SELECTED HDAC ENZYMES 181
HDAC INHIBITOR CLINICAL TRIALS (CONTINUED) 182
DNMT INHIBITORS CLINICAL TRIALS 183
TABLE 59 DNMT INHIBITOR CLINICAL TRIALS SUMMARY 183
DNMT INHIBITORS CLINICAL TRIALS (CONTINUED) 184
EPIGENETIC DRUGS FOR NON-CANCER INDICATIONS 185
TABLE 60 EPIGENETIC NON-CANCER DRUG LANDSCAPE 186
EPIGENETIC DRUGS FOR NON-CANCER ... (CONTINUED) 187
CHAPTER TWELVE: MARKET GROWTH DRIVING FORCES
EPIGENETICS SCIENTIFIC PUBLICATIONS 188
FIGURE 34 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO EPIGENETICS (NUMBER OF PUBLICATIONS) 188
GROWTH DRIVING FORCES 189
TABLE 61 FORCES DRIVING EPIGENOMICS INDUSTRY GROWTH 189
GROWTH IN FUNDING FOR LIFE-SCIENCE RESEARCH 189
TABLE 62 STIMULUS FUNDING ALLOCATED TO UNITED STATES SCIENCE SPENDING 190
FIGURE 35 ANNUAL NIH FUNDING BUDGET, 2000-2009 ($ MILLIONS) 190
FIGURE 35 (CONTINUED) 191
CREATION OF EPIGENETIC MAPS 191
RANGE OF OCCURRENCE OF EPIGENETIC CHANGES 192
AGING POPULATIONS IN DEVELOPED COUNTRIES 192
NEED FOR BETTER CANCER THERAPIES 193
GROWTH IN PERSONALIZED MEDICINE 193
UNDERSTANDING OF EPIGENETIC PROCESSES BEYOND CANCER 194
CHAPTER THIRTEEN: MARKET ANALYSIS
MARKET SUMMARY 195
TABLE 63 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 195
MARKET SUMMARY (CONTINUED) 196
TABLE 64 GLOBAL VALUE OF EPIGENOMIC PRODUCTS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 197
RESEARCH TOOLS MARKETS 197
GLOBAL SALES BY PRODUCT 197
TABLE 65 GLOBAL VALUE OF EPIGENOMIC ANALYSIS RESEARCH TOOLS, BY PRODUCT TYPE, THROUGH 2014 ($ MILLIONS) 198
Kits 198
Reagents 198
Microarrays and Next Gen Sequencing 198
Microarrays and ... (Continued) 199
EPIGENOMIC KIT SALES BY TECHNOLOGY 200
TABLE 66 GLOBAL VALUE OF EPIGENOMICS RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLION) 200
Epigenomic Kit ... (Continued) 201
TABLE 67 GLOBAL VALUE OF EPIGENOMIC ANALYSIS KITS, BY FORMAT, THROUGH 2014 ($ MILLIONS) 202
DNA METHYLATION ANALYSIS KIT MARKET 202
DNA Methylation ... (Continued) 203
TABLE 68 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY ANALYSIS OBJECTIVE, THROUGH 2014 ($ MILLIONS) 204
TABLE 69 GLOBAL VALUE OF DNA METHYLATION RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 205
TABLE 70 GLOBAL VALUE OF DNA METHYLATION SINGLE LOCI RESEARCH TOOLS KITS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 206
TABLE 71 GLOBAL VALUE OF DNA METHYLATION GENOME-WIDE RESEARCH TOOLS KITS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 207
HISTONE ANALYSIS KIT MARKET 208
TABLE 72 GLOBAL VALUE OF HISTONE ANALYSIS KITS, BY TECHNOLOGY FORMAT, THROUGH 2014 ($ MILLIONS) 208
EPIGENETICS MICROARRAY MARKETS 208
MICROARRAYS AND NEXT GEN SEQUENCING AS DOWNSTREAM TOOLS 209
MICROARRAY MARKET 209
TABLE 73 GLOBAL VALUE OF EPIGENOMIC MICROARRAYS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 210
RESEARCH TOOLS REAGENTS MARKET 211
TABLE 74 GLOBAL VALUE OF RESEARCH TOOLS EPIGENOMIC REAGENTS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 211
CHAPTER FOURTEEN: EPIGENOMIC DIAGNOSTICS MARKET
OVERVIEW OF CANCER DIAGNOSTICS MARKET 212
TABLE 75 VALUE OF GLOBAL MOLECULAR DIAGNOSTICS PRODUCTS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 212
CANCER MOLECULAR DIAGNOSTICS GROWTH DRIVERS 213
EPIGENETICS-BASED DIAGNOSTICS MARKETS 213
TABLE 76 PROJECTED CHANGE IN AGE 65-PLUS POPULATION BY REGION (%) 214
Epigenetics-based ... (Continued) 215
TABLE 77 U.S. CANCER INCIDENCE AND ESTIMATED TREATMENT DECISIONS, 2009 216
TABLE 78 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 217
TABLE 79 GLOBAL VALUE OF EPIGENETIC DIAGNOSTIC ASSAYS, BY CANCER INDICATION, THROUGH 2014 ($ MILLIONS) 218
Epigenetics-based ... (Continued) 219
CHAPTER FIFTEEN: EPIGENETIC DRUGS MARKETS
OVERVIEW 220
CANCER DRUG MARKET GROWTH DRIVING FORCES 220
CANCER DRUG MARKET ... (CONTINUED) 221
CLINICAL PROOF OF PRINCIPLE OF EPIGENETIC DRUGS IS ESTABLISHED 222
EPIGENETIC THERAPIES BEYOND CANCER 223
EPIGENETIC DRUG MARKET SUMMARY 223
TABLE 80 GLOBAL VALUE OF EPIGENETIC DRUGS, BY CANCER INDICATION, THROUGH 2014 ($ MILLIONS) 224
Hematological 224
Hematological (Continued) 225
Solid Tumors 226
Solid Tumors (Continued) 227
Solid Tumors (Continued) 228
EPIGENETIC DRUG MARKET BY DRUG CLASS 229
TABLE 81 GLOBAL VALUE OF EPIGENETIC DRUGS, BY DRUG CLASS, THROUGH 2014 ($ MILLIONS) 229
HDAC INHIBITORS MARKETS 229
Strategic Opportunities in HDAC Inhibitors 230
TABLE 82 SUMMARY OF HDAC INHIBITOR STRATEGIC OPPORTUNITIES FOR CANCER TREATMENT 230
HDAC Inhibitor Drug Market Size by Indication 231
TABLE 83 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 232
HDAC Inhibitor Market Size by Technology 233
TABLE 84 GLOBAL VALUE OF HDAC INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 233
DNMT INHIBITORS MARKET 234
TABLE 85 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 235
TABLE 86 GLOBAL VALUE OF DNMT INHIBITOR DRUGS, BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 236
HEMATOLOGICAL CANCER EPIGENETIC DRUG MARKET 236
OVERVIEW OF HEMATOLOGICAL CANCERS 236
TABLE 87 OVERVIEW OF MAJOR HEMATOLOGICAL MALIGNANCIES 237
Overview of Hematological Cancers (Continued) 238
TABLE 88 MDS DRUG COMPARISON 239
HEMATOLOGICAL DRUG MARKET BY INDICATION 240
TABLE 89 HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 240
HDAC Hematological Drug Market 241
TABLE 90 HDAC HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 241
HDAC Hematological ... (Continued) 242
TABLE 91 COMPARISON OF THE PTCL DRUGS, FOLYTYN AND ISTODAX 243
DNMT Hematological Drug Market 243
TABLE 92 DNMT HEMATOLOGICAL CANCER EPIGENETIC DRUGS, BY INDICATION, THROUGH 2014 ($ MILLIONS) 244
CHAPTER SIXTEEN: CELL THERAPY ASSAYS MARKETS
TABLE 93 EPIGENETIC CELL THERAPIES MARKETS, BY APPLICATION, THROUGH 2014 ($ MILLIONS) 245
CELL THERAPY ASSAYS MARKETS (CONTINUED) 246
CHAPTER SEVENTEEN: GEOGRAPHICAL MARKETS
TABLE 94 EPIGENOMIC RESEARCH TOOLS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 247
TABLE 95 EPIGENOMIC DIAGNOSTICS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 248
TABLE 96 NUMBER OF HOSPITALS AND CLINICS, BY GEOGRAPHICAL REGION 248
TABLE 97 EPIGENOMIC PHARMACEUTICALS MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 249
TABLE 98 EPIGENOMIC CELL THERAPIES MARKETS, BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 250
CHAPTER EIGHTEEN: COMPETITOR AND INDUSTRY DYNAMICS
RESEARCH TOOLS 251
TABLE 99 SCOPE OF EPIGENOMIC RESEARCH TOOLS SUPPLIERS 252
FIGURE 36 CHIP-GRADE ANTIBODY SUPPLIER MARKET SHARES, 2009 (%) 253
FIGURE 36 (CONTINUED) 254
DIAGNOSTICS 254
SKILL SET FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES 254
SHIFTING PARADIGM IN DIAGNOSTICS 255
IN-VITRO DIAGNOSTICS COMPETITORS 256
TABLE 100 IN-VITRO DIAGNOSTICS COMPETITORS 256
In-Vitro Diagnostics ... (Continued) 257
TABLE 101 STRATEGIC ALLIANCE STATUS FOR BIOTECHNOLOGY EPIGENETICS DIAGNOSTICS FIRMS 258
TABLE 102 COMPETITIVE LANDSCAPE FOR MOLECULAR DIAGNOSTICS TECHNOLOGIES 259
EPIGENETIC DRUGS INDUSTRY 259
TABLE 103 RELATIVE STRATEGIC POSITION FOR EPIGENOMIC DRUG COMPANIES 260
FIGURE 37 EPIGENOMIC DRUG COMPANY MARKET SHARES, 2009 261
EPIGENOMIC INDUSTRY STRATEGIC ALLIANCES 262
TABLE 104 EPIGENOMICS STRATEGIC ALLIANCES: 2007-2010 263
TABLE 104 (CONTINUED) 264
EPIGENOMIC INDUSTRY .... (CONTINUED) 265
EPIGENOMIC INDUSTRY ... (CONTINUED) 266
EPIGENOMICS INDUSTRY ACQUISITIONS 267
TABLE 105 EPIGENOMICS INDUSTRY ACQUISITIONS, 2007-2010 268
EPIGENOMICS INDUSTRY ... (CONTINUED) 269
CHAPTER NINETEEN: PATENTS
EPIGENOMICS PATENT ACTIVITY 270
FIGURE 38 NUMBER OF EPIGENOMICS PATENTS, BY YEAR, 2000-2009 270
FIGURE 39 NUMBER OF EPIGENOMICS PATENTS, BY GEOGRAPHY, 2000-2009 271
FIGURE 39 (CONTINUED) 272
RESEARCH TOOLS AND DIAGNOSTICS PATENT ACTIVITY 272
TABLE 106 EPIGENOMICS AG RESEARCH TOOLS PATENT COVERAGE 272
RESEARCH TOOLS AND ... (CONTINUED) 273
FIGURE 40 BIOTECHNOLOGY DIAGNOSTICS PATENTS, BY COMPANY (%) 274
TABLE 107 PATENT STATUS FOR BIOTECHNOLOGY DIAGNOSTICS COMPANIES 275
PHARMACEUTICALS PATENTS ACTIVITY 276
TABLE 108 HDAC INHIBITOR PATENT CLAIMS, 2004-2006 276
TABLE 108 (CONTINUED) 277
FIGURE 41 NUMBER OF EPIGENOMICS DRUG PATENTS, BY TECHNOLOGY CLASS AND GEOGRAPHY 278
PHARMACEUTICALS PATENTS ACTIVITY (CONTINUED) 279
FIGURE 42 NUMBER OF HDAC INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY 280
FIGURE 43 NUMBER OF DNMT INHIBITOR PATENTS, BY COMPANY AND GEOGRAPHY 281
PATENT CASE STUDIES 282
CHAPTER TWENTY: COMPANY PROFILES
ABBOTT LABORATORIES 283
ABCAM PLC. 284
ACCESS PHARMACEUTICALS 285
ACETYLON PHARMACEUTICALS 286
ACTIVE MOTIF 286
AFFYMETRIX, INC. 287
AFFYMETRIX, INC. (CONTINUED) 288
TABLE 109 AFFYMETRIX STRATEGIC ALLIANCES 289
TABLE 109 (CONTINUED) 290
AGILENT TECHNOLOGIES, INC. 291
ARNO THERAPEUTICS, INC. 292
ARUP LABORATORIES, INC. 293
ASTELLAS PHARMA, INC. 293
BAYER AG 294
BIOFIELD CORP. 295
BIOSERVE BIOTECHNOLOGIES, LTD. 295
BIOVISION 295
CELGENE CORPORATION 296
CELGENE CORPORATION (CONTINUED) 297
CELLARTIS AB 298
CELLCENTRIC LTD. 298
CELLERON THERAPEUTICS LTD. 299
CELLZOME AG 300
CHIPSCREEN BIOSCIENCES LTD. 301
CHROMA THERAPEUTICS LTD. 302
CLAVIS PHARMA ASA 302
TABLE 110 CLAVIS PHARMA DRUG PIPELINE 303
CONSTELLATION PHARMACEUTICALS 304
CRYSTAL GENOMICS, INC. 304
CURIS 305
EISAI CO. LTD. 305
EPIGENOMICS AG 306
EPIGENOMICS AG (CONTINUED) 307
EPIGENTEK 308
EPITHERAPEUTICS 309
ELIXIR PHARMACEUTICALS, INC. 309
ENVIVO PHARMACEUTICALS 310
EOS SPA 311
EPIONTIS GMBH 311
EPIZYME, INC. 312
ES CELL INTERNATIONAL PTE LTD 313
EXONHIT THERAPEUTICS SA 313
F. HOFFMANN-LA ROCHE, LTD. 314
GENEXTRA S.P.A 315
GENPATHWAY, INC. 316
GLAXOSMITHKLINE 316
GLAXOSMITHKLINE (CONTINUED) 317
HUYA BIOSCIENCE INTERNATIONAL 318
ILLUMINA, INC. 319
ILLUMINA, INC. (CONTINUED) 320
TABLE 111 ILLUMINA SEQUENCING TECHNOLOGY SPACE 321
IMAGENES GMBH 322
INTERNATIONAL DRUG DISCOVERY INSTITUTE 323
ITALFARMACO SPA 323
JOHNSON & JOHNSON 324
KARUS THERAPEUTICS LTD. 325
LABORATORY CORPORATION OF AMERICA HOLDINGS 326
LES LABORATOIRES SERVIER 327
LIFE TECHNOLOGIES INC. 328
LIFE TECHNOLOGIES INC. (CONTINUED) 329
MERCK KGAA 330
MERCK & CO. INC. 331
METHYLGENE 332
TABLE 112 METHYLGENE HDAC INHIBITOR PRODUCT PIPELINE 333
MILLIPORE 334
NATUREWISE BIOTECH & MEDICALS CORP. 335
NOVARTIS 336
ONCOLYS BIOPHARMA INC. 337
ONCOMETHYLOME SCIENCES S.A. 338
TABLE 113 ONCOMETHYLOME DNA METHYLATION DIAGNOSTICS PIPELINE 339
ONCOMETHYLOME SCIENCES S.A. (CONTINUED) 340
ORCHID CHEMICALS & PHARMACEUTICALS LIMITED 341
ORION GENOMICS 342
TABLE 114 ORION STRATEGIC ALLIANCES 343
TABLE 115 ORION EPIGENETIC DIAGNOSTICS PIPELINE 344
ORTHO BIOTECH 345
PACIFIC BIOSCIENCES 345
PHARMACYCLICS 346
PROGEN PHARMACEUTICALS LTD. 347
PROGEN PHARMACEUTICALS LTD. (CONTINUED) 348
PROGNOSDX HEALTH, INC. 349
QUEST DIAGNOSTICS 349
ROCHE LIFE SCIENCES 350
ROCHE LIFE SCIENCES (CONTINUED) 351
ROCHE LIFE SCIENCES (CONTINUED) 352
QIAGEN GMBH 353
RAINDANCE TECHNOLOGIES 354
REACTION BIOLOGY CORP. 354
REPLIGEN CORPORATION 355
RUBICON GENOMICS 355
RUBICON GENOMICS (CONTINUED) 356
S*BIO PTE LTD 357
TABLE 116 S*BIO HDAC INHIBITOR DRUG PIPELINE 358
SCHERING PLOUGH CORPORATION 358
SCOTTISH BIOMEDICAL LTD. 359
SEQUENOM, INC. 360
SEQUENOM, INC. (CONTINUED) 361
SEQWRIGHT 362
SUPERGEN, INC. 362
SYNDAX PHARMACEUTICALS, INC. 363
TABLE 117 ENTINOSTAT CLINICAL TRIALS SUMMARY STATUS 363
SYSMEX CORPORATION 364
TAIHO PHARMACEUTICALS 365
TAKEDA PHARMACEUTICAL COMPANY LIMITED 365
TARGECEPT, INC. 366
THEREPI INC. 366
TOPOTARGET A/S 366
TOPOTARGET A/S (CONTINUED) 367
TOPOTARGET A/S (CONTINUED) 368
TABLE 118 TOPOTARGET'S HDAC INHIBITOR PATENT PORTFOLIO 369
VALIBIO SA 370
VALIRX 371
VERIDEX LLC 371
ZYMO RESEARCH 372
To order this report:
Genomics Industry: Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
